Trial results

A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

NCT06045221 on ClinicalTrials.gov · last registry update 2025-09-22

An unusually large phase 3: 1,698 participants, more than double the 424 typical for the stage. The sponsor logged completion for 22 August 2025. Primary outcome, as filed: Change from Baseline in Hemoglobin A1c (HbA1c). semaglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status

COMPLETED

Phase

P3

Drug

semaglutide

Wegovy, Ozempic, Rybelsus

Sponsor

Eli Lilly and Company

Sponsor type

Industry

Enrollment

1,698

Started

2023-09-22

Primary completion

2025-08-22 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change from Baseline in Hemoglobin A1c (HbA1c)

Conditions studied

Type 2 Diabetes

Every field above is taken directly from the registry record. See all detected changes across the class, or the semaglutide page for this molecule’s full trial and approval history.